Skip to content

Welcome to the Bacteriophage Therapy Summit 2020

The only industry-focused forum dedicated to facilitating the discovery, translation & acceleration of bacteriophage research into targeted therapeutics with clinically significant results.

As phage therapy offers an opportunity to tackle the ever-growing problem of antibiotic resistant infections, the 2nd Bacteriophage Therapy Summit returns to not only drive forward the translation of phage pharmacology into the clinic but also generate discussion around the direction that phage therapy is heading and how this can be commercialized and delivered into the hands of physicians and patients in need.

The 2nd Bacteriophage Therapy Summit is a dedicated scientific and networking forum for large pharma, biotechs and research institutes to capitalize on this re-emerging therapeutic class.

With a clear focus on overcoming the translational and development challenges of this re-emerging therapeutic class, join your peers to be part of the discussion to facilitate the translation of phage products into targeted, clinically successful therapeutics

Top 5 Reasons to Attend

Develop Capture

Develop a greater
understanding of how to navigate regulatory hurdles in CMC and clinical development from returning FDA speaker as well as the first appearance of the EMA

Understand Capture

Understand the best approach to designing and undertaking clinical trials with a recent clinical case study from BiomX

Learn Capture

Learn about the scalable methods of formulation and encapsulation as well as the unique aspects of phage product
manufacturing with experts from Armata Pharmaceutical and Loughborough University

Gain Capture

Gain insights into the approaches to overcome bacterial resistance to ensure phage therapy is a long-term viable treatment option from Adaptive Phage Therapeutics, Bioharmony Therapeutics and MIT

Uncover Capture

Uncover the various therapeutic uses of phages including using phages as delivery vehicles and resurrecting bacterial sensitivity to antibiotics with talks from Eligo Bioscience and Nemesis Bioscience